Implied IWR Analyst Target Price: $81
NASDAQ · 2d ago
Here's Why Guardant Health (GH) Looks Ripe for Bottom Fishing
NASDAQ · 5d ago
Insiders pour millions into these 2 stocks — this is what makes them attractive buys
TipRanks · 03/21 14:43
Health Care Sector Update for 03/16/2023: GH, MGNX, ESPR
NASDAQ · 03/16 18:11
Guru Fundamental Report for GH
NASDAQ · 03/16 16:08
Guardant Health Earnings Perspective: Return On Capital Employed
Benzinga · 03/16 14:46
Thursday 3/16 Insider Buying Report: GH, SCHW
NASDAQ · 03/16 14:35
Insider Buy: Guardant Health
Insider Buy: Guardant Health
MT Newswires · 03/16 00:53
First Week of GH October 20th Options Trading
NASDAQ · 03/14 14:59
SVB Securities Sticks to Their Buy Rating for Guardant Health (GH)
TipRanks · 03/13 18:25
BRIEF-Guardant Health Holds No Deposits Or Investments At SVB
Reuters · 03/13 11:21
Guardant seeks FDA approval of colorectal cancer detection blood test
Seeking Alpha · 03/10 13:25
BRIEF-Guardant Health Submits Premarket Approval Application To The U.S. Food And Drug Administration For Shield™ Blood Test
Reuters · 03/10 13:09
Guardant Health Applies to US FDA for Premarket Approval of Colorectal Cancer Blood Test
Guardant Health Applies to US FDA for Premarket Approval of Colorectal Cancer Blood Test
MT Newswires · 03/10 09:42
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
Benzinga · 03/09 15:00
Exact upgraded, Guardant downgraded as Citi revisits diagnostics coverage
Seeking Alpha · 03/09 13:34
Sermonix Pharma And Guardant Health Initiated Phase 3 Study Comparing Lasofoxifene Plus Abemaciclib Combo Vs. Fulvestrant Plus Abemaciclib In Pre-And Post-Menopausal Subjects With Locally Advanced Or Metastatic ER+/HER2-Breast Cancer With ESR1 Mutation
Benzinga · 03/09 13:29
BRIEF-Sermonix Pharmaceuticals - Announces Initiation Of Phase 3 Elaine-3 Study
Reuters · 03/09 13:15
Citigroup Downgrades Guardant Health to Neutral, Lowers Price Target to $33
Benzinga · 03/09 11:07
--Citigroup Downgrades Guardant Health to Neutral From Buy, Cuts Price Target to $33 From $60
--Citigroup Downgrades Guardant Health to Neutral From Buy, Cuts Price Target to $33 From $60
MT Newswires · 03/09 10:16
Webull provides a variety of real-time GH stock news. You can receive the latest news about Guardant Health through multiple platforms. This information may help you make smarter investment decisions.
About GH
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets and advanced analytics. The Company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. It also has developed Guardant360 TissueNext tissue test for advanced-stage cancer, Guardant Reveal blood test to detect residual and recurring disease in early-stage cancer patients, and Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging. The Company’s GuardantINFORM platform is used to help biopharmaceutical companies accelerate precision oncology drug development through the use of this in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers.